{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:48:45Z","timestamp":1781261325589,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07047-w","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T09:40:30Z","timestamp":1754041230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Improved survival with high albumin leakage in patients with protein-energy wasting and inflammation on hemodialysis and online hemodiafiltration"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0725-2688","authenticated-orcid":false,"given":"Kazuyoshi","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Michiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiyo","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6453-3824","authenticated-orcid":false,"given":"Takahiro","family":"Kuragano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Minakuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"7047_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/s0272-6386(12)70364-5","volume":"15","author":"EG Lowrie","year":"1990","unstructured":"Lowrie, E. G. & Lew, N. L. Death risk in Hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 15, 458\u2013482. https:\/\/doi.org\/10.1016\/s0272-6386(12)70364-5 (1990).","journal-title":"Am. J. Kidney Dis."},{"key":"7047_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1681\/ASN.2008060590","volume":"20","author":"F Locatelli","year":"2009","unstructured":"Locatelli, F. et al. Effect of membrane permeability on survival of Hemodialysis patients. J. Am. Soc. Nephrol. 20, 645\u2013654. https:\/\/doi.org\/10.1681\/ASN.2008060590 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7047_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s41100-021-00385-1","volume":"7","author":"K Okada","year":"2021","unstructured":"Okada, K. et al. Effects of Japanese-style online hemodiafiltration on survival and cardiovascular events. Ren. Replace. Ther. 7, 70. https:\/\/doi.org\/10.1186\/s41100-021-00385-1 (2021).","journal-title":"Ren. Replace. Ther."},{"key":"7047_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s41100-022-00440-5","volume":"8","author":"K Okada","year":"2022","unstructured":"Okada, K. et al. Effects of high albumin leakage on survival between online hemodiafiltration and super high-flux hemodialysis: the HISTORY study. Ren. Replace. Ther. 8, 52. https:\/\/doi.org\/10.1186\/s41100-022-00440-5 (2022).","journal-title":"Ren. Replace. Ther."},{"key":"7047_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/ckj\/sfab177","volume":"15","author":"M Abe","year":"2021","unstructured":"Abe, M. et al. Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study. Clin. Kidney J. 15, 473\u2013483. https:\/\/doi.org\/10.1093\/ckj\/sfab177 (2021).","journal-title":"Clin. Kidney J."},{"key":"7047_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s41100-023-00490-3","volume":"9","author":"K Okada","year":"2023","unstructured":"Okada, K. et al. Comparison of survival for super high-flux Hemodialysis (SHF-HD) with high albumin leakage versus online hemodiafiltration or SHF-HD with low albumin leakage: the SUPERB study. Ren. Replace. Ther. 9, 32. https:\/\/doi.org\/10.1186\/s41100-023-00490-3 (2023).","journal-title":"Ren. Replace. Ther."},{"key":"7047_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1681\/ASN.2012080875","volume":"24","author":"F Maduell","year":"2013","unstructured":"Maduell, F. et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in Hemodialysis patients. J. Am. Soc. Nephrol. 24, 487\u2013497. https:\/\/doi.org\/10.1681\/ASN.2012080875 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7047_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1681\/ASN.2011121140","volume":"23","author":"MPC Grooteman","year":"2012","unstructured":"Grooteman, M. P. C. et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J. Am. Soc. Nephrol. 23, 1087\u20131096. https:\/\/doi.org\/10.1681\/ASN.2011121140 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7047_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ndt\/gfs407","volume":"28","author":"E Ok","year":"2013","unstructured":"Ok, E. et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF study. Nephrol. Dial Transpl. 28, 192\u2013202. https:\/\/doi.org\/10.1093\/ndt\/gfs407 (2013).","journal-title":"Nephrol. Dial Transpl."},{"key":"7047_CR10","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.kint.2017.01.013","volume":"91","author":"M Morena","year":"2017","unstructured":"Morena, M. et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux Hemodialysis in the elderly. Kidney Int. 91, 1495\u20131509. https:\/\/doi.org\/10.1016\/j.kint.2017.01.013 (2017).","journal-title":"Kidney Int."},{"key":"7047_CR11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1056\/NEJMoa2304820","volume":"389","author":"PJ Blankestijn","year":"2023","unstructured":"Blankestijn, P. J. et al. Effect of hemodiafiltration or Hemodialysis on mortality in kidney failure. N Engl. J. Med. 389, 700\u2013709. https:\/\/doi.org\/10.1056\/NEJMoa2304820 (2023).","journal-title":"N Engl. J. Med."},{"key":"7047_CR12","doi-asserted-by":"publisher","first-page":"e0150003","DOI":"10.1371\/journal.pone.0150003","volume":"11","author":"Y Sakao","year":"2016","unstructured":"Sakao, Y. et al. Serum creatinine modifies associations between body mass index and mortality and morbidity in prevalent Hemodialysis patients. PLoS ONE. 11, e0150003. https:\/\/doi.org\/10.1371\/journal.pone.0150003 (2016).","journal-title":"PLoS ONE"},{"key":"7047_CR13","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.2215\/CJN.00710111","volume":"6","author":"J Bazeley","year":"2011","unstructured":"Bazeley, J. et al. C-reactive protein and prediction of 1-year mortality in prevalent Hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6, 2452\u20132461. https:\/\/doi.org\/10.2215\/CJN.00710111 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"7047_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 10, 150\u2013161. https:\/\/doi.org\/10.1002\/pst.433 (2011).","journal-title":"Pharm. Stat."},{"issue":"4 Suppl 2","key":"7047_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.mcg.0000155514.17715.39","volume":"39","author":"M Chojkier","year":"2005","unstructured":"Chojkier, M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J. Clin. Gastroenterol. 39 (4 Suppl 2), 143\u2013146. https:\/\/doi.org\/10.1097\/01.mcg.0000155514.17715.39 (2005).","journal-title":"J. Clin. Gastroenterol."},{"key":"7047_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s10047-016-0900-2","volume":"19","author":"K Nagai","year":"2016","unstructured":"Nagai, K. et al. The effect of albumin leakage in Hemodialysis patients on redox status of serum albumin. J. Artif. Organs. 19, 310\u2013314. https:\/\/doi.org\/10.1007\/s10047-016-0900-2 (2016).","journal-title":"J. Artif. Organs"},{"key":"7047_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1681\/ASN.2009020213","volume":"21","author":"AN Friedman","year":"2010","unstructured":"Friedman, A. N. & Fadem, S. Z. Reassessment of albumin as a nutritional marker in kidney disease. J. Am. Soc. Nephrol. 21, 223\u2013230. https:\/\/doi.org\/10.1681\/ASN.2009020213 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7047_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41100-024-00543-1","volume":"10","author":"K Okada","year":"2024","unstructured":"Okada, K. et al. Improved survival on super high flux-albumin leaking Hemodialysis and online hemodiafiltration in patients with mild hypoalbuminemia: evidence and a hypothesis. Ren. Replace. Ther. 10, 27. https:\/\/doi.org\/10.1186\/s41100-024-00543-1 (2024).","journal-title":"Ren. Replace. Ther."},{"key":"7047_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/ars.2011.4282","volume":"17","author":"MG Olsson","year":"2012","unstructured":"Olsson, M. G. et al. Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for \u03b11-microglobulin. Antioxid. Redox Signal. 17, 813\u2013846. https:\/\/doi.org\/10.1089\/ars.2011.4282 (2012).","journal-title":"Antioxid. Redox Signal."},{"key":"7047_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1046\/j.1523-1755.1998.00729.x","volume":"53","author":"de Sain-van","year":"1998","unstructured":"de Sain-van et al. Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: measurements with stable isotopes. Kidney Int. 53, 181\u2013188. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00729.x (1998).","journal-title":"Kidney Int."},{"key":"7047_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12882-023-03317-9","volume":"24","author":"K Boss","year":"2023","unstructured":"Boss, K. et al. Albumin redox state of maintenance haemodialysis patients is positively altered after treatment. BMC Nephrol. 24, 273. https:\/\/doi.org\/10.1186\/s12882-023-03317-9 (2023).","journal-title":"BMC Nephrol."},{"key":"7047_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1744-9987.2010.00841.x","volume":"14","author":"H Terawaki","year":"2010","unstructured":"Terawaki, H. et al. The redox state of albumin and serious cardiovascular incidence in Hemodialysis patients. Ther. Apher Dial. 14, 465\u2013471. https:\/\/doi.org\/10.1111\/j.1744-9987.2010.00841.x (2010).","journal-title":"Ther. Apher Dial"},{"key":"7047_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12882-019-1669-3","volume":"21","author":"TH 23 Kim","year":"2020","unstructured":"23 Kim, T. H. et al. Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study. BMC Nephrol. 21, 2. https:\/\/doi.org\/10.1186\/s12882-019-1669-3 (2020).","journal-title":"BMC Nephrol."},{"key":"7047_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/toxins14110779","volume":"14","author":"YG Kim","year":"2022","unstructured":"Kim, Y. G. et al. The medium cut-off membrane does not lower protein-bound uremic toxins. Toxins 14, 779. https:\/\/doi.org\/10.3390\/toxins14110779 (2022).","journal-title":"Toxins"},{"key":"7047_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.nefro.2017.03.013","volume":"38","author":"F Maduella","year":"2018","unstructured":"Maduella, F. et al. Evaluation of the dialyzer inner diameter in online haemodiafiltration. Nefrologia (Engl Ed). 38, 34\u201340. https:\/\/doi.org\/10.1016\/j.nefro.2017.03.013 (2018).","journal-title":"Nefrologia (Engl Ed)"},{"key":"7047_CR26","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/ndt\/gfx191","volume":"33","author":"MK van Gelder","year":"2018","unstructured":"van Gelder, M. K. et al. Albumin handling in different Hemodialysis modalities. Nephrol. Dial Transpl. 33, 906\u2013913. https:\/\/doi.org\/10.1093\/ndt\/gfx191 (2018).","journal-title":"Nephrol. Dial Transpl."},{"key":"7047_CR27","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.ekir.2020.08.013","volume":"5","author":"H Komaba","year":"2020","unstructured":"Komaba, H. et al. Fibroblast growth factor 23 and mortality among prevalent Hemodialysis patients in the Japan Dialysis outcomes and practice patterns study. Kidney Int. Rep. 5, 1956\u20131964. https:\/\/doi.org\/10.1016\/j.ekir.2020.08.013 (2020).","journal-title":"Kidney Int. Rep."},{"key":"7047_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41100-025-00604-z","volume":"11","author":"K Okada","year":"2025","unstructured":"Okada, K. et al. High albumin leakage rather than increased dialysis dose can increase the \u03b11\u2013microglobulin reduction ratio in patients on predilution online hemodiafiltration. Ren. Replace. Ther. 11, 9. https:\/\/doi.org\/10.1186\/s41100-025-00604-z (2025).","journal-title":"Ren. Replace. Ther."},{"key":"7047_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/ndt\/gfx277","volume":"33","author":"F Locatelli","year":"2018","unstructured":"Locatelli, F. et al. Mortality risk in patients on hemodiafiltration versus hemodialysis: a \u2018real-world\u2019 comparison from the DOPPS. Nephrol. Dial Transpl. 33, 683\u2013689. https:\/\/doi.org\/10.1093\/ndt\/gfx277 (2018).","journal-title":"Nephrol. Dial Transpl."},{"key":"7047_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/1744-9987.13508","volume":"25","author":"T Thammathiwat","year":"2021","unstructured":"Thammathiwat, T. et al. Super high-flux Hemodialysis provides comparable effectiveness with high-volume postdilution online hemodiafiltration in removing protein-bound and middle-molecule uremic toxins: A prospective cross-over randomized controlled trial. Ther. Apher Dial. 25, 73\u201381. https:\/\/doi.org\/10.1111\/1744-9987.13508 (2021).","journal-title":"Ther. Apher Dial"},{"key":"7047_CR31","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3390\/jcm13071865","volume":"13","author":"M Tashiro","year":"2024","unstructured":"Tashiro, M. et al. Impact of albumin leakage on the mortality of patients receiving Hemodialysis or online hemodiafiltration. J. Clin. Med. 13, 1865. https:\/\/doi.org\/10.3390\/jcm13071865 (2024).","journal-title":"J. Clin. Med."},{"key":"7047_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4009\/jsdt.49.697","volume":"4","author":"M Mineshima","year":"2016","unstructured":"Mineshima, M. et al. 2016 update Japanese society for dialysis therapy standard of fluids for Hemodialysis and related therapies. Ren. Replace. Ther. 4, 15. https:\/\/doi.org\/10.4009\/jsdt.49.697 (2016).","journal-title":"Ren. Replace. Ther."},{"key":"7047_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(16)30448-2","volume":"388","author":"Robinson","year":"2016","unstructured":"RobinsonBM et al. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet 388, 294\u2013306. http:\/\/doi.org\/0.1016\/S0140-6736(16)30448-2 (2016).","journal-title":"Lancet"},{"key":"7047_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000339940","volume":"36","author":"R Takahashi","year":"2012","unstructured":"Takahashi, R. et al. Combined values of serum albumin, C-reactive protein and body mass index at dialysis initiation accurately predicts long-term mortality. Am. J. Nephrol. 36, 136\u2013143. https:\/\/doi.org\/10.1159\/000339940 (2012).","journal-title":"Am. J. Nephrol."},{"key":"7047_CR35","doi-asserted-by":"publisher","first-page":"e0190410","DOI":"10.1371\/journal.pone.0190410","volume":"13","author":"FC Alves","year":"2018","unstructured":"Alves, F. C. et al. The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. PLoS ONE. 13, e0190410. https:\/\/doi.org\/10.1371\/journal.pone.0190410 (2018).","journal-title":"PLoS ONE"},{"key":"7047_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s41100-019-0248-1","volume":"5","author":"K Nitta","year":"2019","unstructured":"Nitta, K. et al. Annual dialysis data report 2017, JSDT renal data registry. Ren. Replace. Ther. 5, 53. https:\/\/doi.org\/10.1186\/s41100-019-0248-1 (2019).","journal-title":"Ren. Replace. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07047-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07047-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07047-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:43:50Z","timestamp":1757328230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07047-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7047"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07047-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.O., M.T., H.M., T.I., and J.M. received funding for specific clinical research (Japan Registry of Clinical Trials registration number jRCTs032220723) from Nipro Co., Ltd. and specific clinical research (Japan Registry of Clinical Trials with the registration number jRCTs062190020) from Asahi Kasei Medical Co., Ltd.\u3000K.O. reports personal fees from Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., AstraZeneca Plc., Torii Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Kowa Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Eli Lilly Japan K.K. M. T. reports personal fees from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Toray Medical Co., Ltd., Novartis Pharm Co. Ldt., Otsuka Pharmaceutical Co., Ltd., Nova Biomedical Co., Ldt., and JMS Co. Ldt. H.M. reports personal fees from JMS Co. Ldt. and Fuso Pharmaceutical Industries, Ltd\u2026T.I. reports personal fees from Nipro Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca Plc., Torii Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Terumo Co. Ltd., JMS Co. Ldt., and Fuso Pharmaceutical Industries, Ltd. T.K. reports personal fees from Kyowa Kirin Co., Ltd., personal fees from Astellas Pharma Inc., personal fees from Bayer Yakuhin, Ltd., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants from Kissei Pharmaceutical Co., Ltd., personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Vantive Japan, personal fees from AstraZeneca Plc., personal fees from Torii Pharmaceutical Co., Ltd, personal fees from Sanwa Kagaku Kenkyusho Co., Ltd, and personal fees from Kaneka Medical products. J.M. reports personal fees from Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Vantive Japan, AstraZeneca Plc., Torii Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Novartis Pharm Co. Ldt., Otsuka Pharmaceutical Co., Ltd., Chugai Parmaceutical Co., Ltd., Terumo Co. Ltd., and JMS Co. Ldt. S.Y. has no Conflict of Interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28090"}}